Simultaneously, a nationwide retrospective observational study that estimated the effect of SGLT2 inhibitors on hHF among diabetes patients suggests that SGLT2 inhibitors reduced hHF compared with dipeptidyl peptidase-4 inhibitors. The gene discussed is SLC5A2; the disease is diabetes mellitus.